- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01601548
Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy
November 29, 2017 updated by: Masonic Cancer Center, University of Minnesota
Upon the completion of aggressive chemotherapy and radiation for curative intent cancers, many cancer survivors suffer from a myriad of symptoms ranging from physical symptoms such as hot flashes, insomnia, and fatigue to psychosocial symptoms including depression and anxiety.
Mindfulness Based Cancer Recovery (MBCR) is a type of mind-body intervention.
Mind-body interventions are defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
MBCR is a step wise standardized behavioral intervention of MBSR.
The program is usually conducted in eight weekly class sessions that are 2-2.5 hours in length.
During class sessions, participants are presented with mindfulness meditation techniques and share their experiences related to these meditation practices.
There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day.
In addition to home meditation practice there are often reading assignments and reflective exercises that relate to mindfulness.
A full day retreat generally occurs in the second half of the course, providing an opportunity for class participants to gain extended experience with mindfulness techniques.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stage I-III breast cancer, gynecologic cancer or colorectal cancer
- Cancer survivor at least 18 years of age at the time of study enrollment
- Completed chemotherapy within the past six months at the time of consent (adjuvant hormone therapy is allowed)
Exclusion Criteria:
- Psychologic disease in which informed consent cannot be obtained from the subject
- Need for ongoing chemotherapy and/or radiation therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention Arm
Subjects are randomized to the Mindfulness Based Cancer Recovery (MBSR) intervention.
Participants are presented with mindfulness medication techniques and share their experiences related to these meditation practices.
There is a home practice component with an expectation of regular home meditation practice of 45 minutes per day.
A full day silent retreat will occur in the second half of the course, providing an opportunity for class participants to gain experience with mindfulness techniques.
|
Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being.
MBCR is a psycho-educational program developed by Dr. Linda Carlson.
It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
|
|
NO_INTERVENTION: Control Arm
No intervention is administered.
Health-related quality of life questionnaires will be completed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Medical Outcomes Study Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
MOS SF-36: Medical Outcomes Study 36-Item Short-Form
|
Day 1, Week 8 and 4 Month Follow-Up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Functional Assessment in Cancer Therapy Fatigue Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
FACT-F: Functional Assessment in Cancer Therapy - Fatigue
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Change in Pittsburgh Sleep Quality Index Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
PSQI: Pittsburgh Sleep Quality Index
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Change in State-Trait Anxiety Inventory Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
20-item State-Trait Anxiety Inventory
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Comparison of Sexual Functioning Scale Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
MOS Sexual Functioning Scale
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Change in Self-Compassion Scale Scores - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
SCS-SF: Self-Compassion Scale - Short Form
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Change in Self-Collected Information - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
Self collected and self-report information regarding weekly meditation practice time, recorded class attendance and information from participants regarding barriers and challenges to practice, and perceived benefits to practice will be collected.
|
Day 1, Week 8 and 4 Month Follow-Up
|
|
Change in Number of Natural Killer Cells - Intervention versus Control
Time Frame: Day 1, Week 8 and 4 Month Follow-Up
|
Day 1, Week 8 and 4 Month Follow-Up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Anne Blaes, M.D., Masonic Cancer Center, University of Minnesota
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (ACTUAL)
July 1, 2013
Study Completion (ACTUAL)
July 1, 2013
Study Registration Dates
First Submitted
April 24, 2012
First Submitted That Met QC Criteria
May 17, 2012
First Posted (ESTIMATE)
May 18, 2012
Study Record Updates
Last Update Posted (ACTUAL)
December 2, 2017
Last Update Submitted That Met QC Criteria
November 29, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012NTLS014
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Mindfulness Based Cancer Recovery
-
University of CalgaryRecruitingBreast Cancer | Colorectal Cancer | Chemotherapy EffectCanada
-
University Hospital, GenevaCompletedGynecologic CancerSwitzerland
-
Linda E. CarlsonAlberta Health services; University of Calgary; Princess Margaret Hospital, Canada and other collaboratorsActive, not recruiting
-
Instituto Portugues de Oncologia, Francisco Gentil...Linnaeus University; University of Oulu; European Commission; Polytechnic Institute... and other collaboratorsUnknown
-
University of HaifaCompletedStress Disorders, Post-Traumatic | Stress Related DisorderIsrael
-
Bout Me HealingCompletedSubstance Use Disorder (SUD) | Anxiety Disorder GeneralizedUnited States
-
Florida State UniversityRecruitingChronic Musculoskeletal PainUnited States
-
VA Office of Research and DevelopmentCompleted
-
Indiana UniversityNational Cancer Institute (NCI); Walther Cancer InstituteCompleted
-
Weill Medical College of Cornell UniversityAvon FoundationCompletedBreast CancerUnited States